IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-05

Study Completion Date

2020-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate point of care SARS-Cov2 Virus IgG/IgM rapid test cassette Clungene test and correlate it with the standard method of testing in inpatients who have tested positive or negative for COVID19.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Validation of an Immunochromatographic Assay for IgG/IgM Antibodies to 2019- nCoV

NCT04434417

COVID

COMPLETED

Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients

NCT04483622

Covid19

COMPLETED

Diagnostic Value of New COVID-19 Antibodies Testing Among Laboratory Healthcare Workers

NCT04445415

COVID-19

UNKNOWN

Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients

NCT04524507

COVID-19

COMPLETED PHASE2

Assessment of the Natural Anticoagulant Profile in Patients With COVID-19

NCT05083104

COVID-19 Patients

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a laboratory testing study using the SARS-Cov2 Virus IgG/IgM rapid test cassette Clungene test to determine the presence of IgM and IgG antibodies in subjects who have tested negative or positive for COVID-19. The study is observational and subjects will be assigned to one of two arms depending on the results of their nCOVID-19 test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A (positive for COVID-19)

One or two samples of your blood that were previously collected for routine care will be obtained from the hospital laboratory and will be tested for the antibodies against COVID-19 virus.

* First blood sample obtained: 7 to 12 days following onset of symptoms; and/or
* Second blood sample obtained: 12 to 40 days following the onset of symptoms.

Clungene rapid test cassette

Intervention Type DIAGNOSTIC_TEST

Blood will be tested for the presence of IgG and IgM antibodies using the Clungene rapid test cassette.

Arm B (negative for COVID-19)

One sample of blood that was collected for routine care at any point during hospitalization will be obtained from the hospital laboratory and will be tested for the antibodies.

Clungene rapid test cassette

Intervention Type DIAGNOSTIC_TEST

Blood will be tested for the presence of IgG and IgM antibodies using the Clungene rapid test cassette.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clungene rapid test cassette

Blood will be tested for the presence of IgG and IgM antibodies using the Clungene rapid test cassette.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Received confirmed COVID-19 positive or negative test from Sharp HealthCare's standard method of testing.
* Age \>/=18 years old.
* Access to a phone in the hospital room or an electronic device that is capable of receiving phone calls and/or video calls and/or e-mail.
* Able to read/write/speak English or Spanish fluently.
* Subjects must have the ability to understand the requirements of the study, provide informed consent, and provide authorization of use and disclosure of personal health information.
* Hospitalized at the time of consent or recently discharged with leftover blood stored at hospital laboratory